Larvol Delta - Viracta-Therapeutics-Announces-Positive-Topline-Nanaval-Results-from-Stage-1-of-the-NAVAL1-Trial-in-Patients-with-Relapsed-or-Refractory-EpsteinBarr-VirusPositive-EBV-Peripheral-TCell-Lymphoma

Valcyte (valganciclovir) - Roche, Mitsubishi Tanabe

nanatinostat (VRx-3996) - Viracta Therap

https://www.globenewswire.com/news-release/2024/04/15/2862733/0/en/Viracta-Therapeutics-Announces-Positive-Topline-Nana-val-Results-from-Stage-1-of-the-NAVAL-1-Trial-in-Patients-with-Relapsed-or-Refractory-Epstein-Barr-Virus-Positive-EBV-Periphera.html

Apr 15, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next